Ofloxacin (ofloxacin)
Last reviewed · Source: First Databank (FDB) drug data
Overview
Ofloxacin is a synthetic fluoroquinolone anti-infective agent.
USES: This medication is used to treat a variety of bacterial infections. Ofloxacin belongs to a class of drugs called quinolone antibiotics. It works by stopping the growth of bacteria.
This antibiotic treats only bacterial infections. It will not work for viral infections (such as common cold, flu). Using any antibiotic when it is not needed can cause it to not work for future infections.
Generic name: ofloxacin
Pronunciation: (oh-FLOX-uh-sin)
Reference product & biosimilars
No reference, biosimilar or interchangeable associated with this drug.
Today’s intelligence on Ofloxacin
Indications
The following indications are listed for Ofloxacin:
- Bacterial Urinary Tract Infection
- Chlamydia Cervicitis
- Chlamydia Trachomatis Pelvic Inflammatory Disease
- Chlamydia Trachomatis Urethritis
- Citrobacter Complicated Uti
- Citrobacter Cystitis
- Complicated E. Coli Uti
- Complicated Proteus Uti
- Complicated Uti With Pseudomonas Aeruginosa
- E. Coli Cystitis
- E. Coli Prostatitis
- Enterobacter Cystitis
- Gram-Negative Aerobic Bacillary Pneumonia
- Haemophilus Influenzae Bronchitis
- Haemophilus Influenzae Pneumonia
- Klebsiella Complicated Uti
- Klebsiella Cystitis
- Lower Respiratory Infection
- Nongonococcal Urethritis
- Pneumonia
- Proteus Cystitis
- Pseudomonas Aeruginosa Cystitis
- Skin And Skin Structure Infection
- Skin And Skin Structure Proteus Infection
- Skin And Skin Structure Streptococcus Pyogenes Infection
- Staphylococcus Aureus Skin And Skin Structure Infection
- Streptococcal Pneumonia
- Streptococcus Pneumoniae Bronchitis
Also known as: Bacterial Infection Of The Prostate Due To E. Coli, Bronchitis Due To Diplococcus Pneumoniae, Bronchitis Due To Fraenkel's Pneumococcus, Bronchitis Due To Fraenkel-Weichselbaum Pneumococcus, Bronchitis Due To H. Flu, Bronchitis Due To H. Influenzae, Bronchitis Due To Haemophilus Influenzae, Bronchitis Due To Hemophilus Influenzae, Bronchitis Due To Influenzae Bacillus, Bronchitis Due To Pfeiffer's Bacillus, Bronchitis Due To Pneumococcus, Bronchitis Due To Pneumonococcus, Bronchitis Due To Streptococcus Pneumoniae, Cervicitis Due To Chlamydia Trachomatis, Complicated Pseudomonas Aeruginosa Urinary Tract Infection, Complicated Urinary Tract Infection Due To Citrobacter, Complicated Urinary Tract Infection Due To Escherichia Coli, Complicated Urinary Tract Infection Due To Klebsiella, Complicated Urinary Tract Proteus Species Infection, Complicated Uti Due To Citrobacter Species, Complicated Uti Due To E. Coli, Complicated Uti Due To Klebsiella Species, Complicated Uti Due To Proteus Species, Complicated Uti Due To Pseudomonas Aeruginosa, Cystitis Due To Aerobacter Species, Cystitis Due To Citrobacter Species, Cystitis Due To E. Coli, Cystitis Due To Enterobacter Species, Cystitis Due To Escherichia Coli, Cystitis Due To Klebsiella Species, Cystitis Due To Proteus Species, Cystitis Due To Pseudomonas Aeruginosa, H. Flu Pneumonia, H. Influenzae Pneumonia, Hemophilus Influenzae Pneumonia, Infection Of Skin And/Or Subcutaneous Tissue, Influenza Bacillus Pneumonia, Lower Respiratory Tract Infection, Ngu Due To Chlamydia Trachomatis, Nongonococcal Urethritis Due To Chlamydia Trachomatis, Pelvic Inflammatory Disease Due To Chlamydia Trachomatis, Pfeiffer's Bacillus Pneumonia, Pid Due To Chlamydia Trachomatis, Pneumonia Due To Gram-Negative Organism, Pneumonia Due To Haemophilus Influenzae, Pneumonia Due To Streptococcus Species, Pneumonia Due To Streptococcus Spp., Prostatitis Due To E. Coli, Prostatitis Due To Escherichia Coli, Skin & Skin Soft Tissue Streptococcus Pyogenes Infection, Skin And Skin Soft Tissue Proteus Infection, Skin And Skin Soft Tissue Staphylococcus Aureus Infection, Skin And Soft Tissue Skin Infection, Trachelitis Due To Chlamydia Trachomatis, Urethritis Due To Chlamydia Trachomatis, Urinary Cystitis Due To Citrobacter Species, Urinary Cystitis Due To Enterobacter Species, Urinary Cystitis Due To Escherichia Coli, Urinary Cystitis Due To Klebsiella Species, Urinary Cystitis Due To Proteus Species, Urinary Cystitis Due To Pseudomonas Aeruginosa.
Dosing
The usual adult oral dosage of ofloxacin is 200-400 mg every 12 hours.
Ofloxacin is administered orally. Although ofloxacin also has been administered IV, a parenteral preparation of the drug is no longer commercially available in the US.
While presence of food in the GI tract can decrease the rate and/or extent of absorption of ofloxacin, this is not usually considered clinically important and the manufacturer states that the drug can be given without regard to meals. Milk and yogurt do not appear to affect GI absorption of ofloxacin. (See Pharmacokinetics: Absorption.)
To minimize the possibility of interference with the GI absorption of ofloxacin, patients should be instructed not to ingest antacids containing calcium, magnesium, or aluminum, sucralfate, metal cations such as iron or zinc (including multivitamin preparations containing zinc), or buffered didanosine preparations concomitantly with or within 2 hours of an ofloxacin dose. (See Drug Interactions.)
Patients receiving ofloxacin should be well hydrated and should be instructed to drink fluids liberally. (See Cautions: Precautions and Contraindications.)
No dosing information is available for this tab.
No dosing information is available for this tab.
Drug interactions
There is no enhanced messaging for this drug.
There are no contraindication interactions for this drug.
There are no severe interactions for this drug.
There are no moderate interactions for this drug.
Contraindications
There is no enhanced messaging for this drug.
There are no contraindication contraindications for this drug.
There are no severe contraindications for this drug.
There are no moderate contraindications for this drug.
Adverse reactions
There is no enhanced messaging for this drug.
There are no severe adverse reactions for this drug.
There are no less severe adverse reactions for this drug.
Precautions
No enhanced messaging available.
No enhanced messaging available.
There are no adequate and controlled studies to date using ofloxacin in pregnant women. Since the drug, like most other fluoroquinolones, causes arthropathy in immature animals, ofloxacin should not be used in pregnant women unless the potential benefits justify the possible risks to the fetus.
Reproduction studies in rats and rabbits using oral ofloxacin in dosages up to 810 and 160 mg/kg daily, respectively, have not revealed evidence of teratogenicity. However, fetotoxicity (decreased fetal body weight and increased fetal mortality) did occur in rats and rabbits receiving oral ofloxacin dosages equivalent to 50 and 10 times the usual human dosage, respectively. In rats receiving ofloxacin dosages of 810 mg/kg daily (more than 50 times the maximum human dosage), retardation in the degree of ossification and minor skeletal variations such as cervical ribs and shortened or absent 13th ribs occurred. Perinatal and postnatal studies in rats using oral dosages up to 360 mg/kg daily revealed a decrease in food intake during gestation and an increase in food and water intake during lactation, but did not reveal evidence of adverse effects on late fetal development, labor, delivery, lactation, neonatal viability, or growth of the offspring.
Ofloxacin is distributed into milk. Because of the potential for serious adverse effects of ofloxacin in nursing infants, a decision should be made whether to discontinue nursing or the drug, taking into account the importance of the drug to the woman.
No enhanced messaging available.
ICD codes
No ICD codes are available for this drug.
Formulary status
Search health-plan coverage for this drug by ZIP code.
Choose the first character of a health plan name.
Last reviewed · Source: First Databank (FDB) drug data
On this page
Actions
Sign in to save favorites
Saving this drug requires a free Physicians Office Resource account.